ChemoCentryx discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. The Company is recognized as a world leader in biology, drug discovery and development based on the chemokine system. ChemoCentryx is developing first-in-class, oral therapies for diseases such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and cancer. ChemoCentryx distinguishes itself through unparalleled chemokine system expertise, innovative technologies and a product-driven approach, which has yielded several exciting drug candidates and the largest pipeline of chemokine-based drugs in the industry.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 08/01/06 | Series C | 17.7M | Jennison Associates LLC, HBM Bioventures, OrbiMed Advisors LLC, Techne Corp., Alta Partners, GIMV | Unknown |
| 03/01/07 | Series D | 30M | GlaxoSmithKline | 188M |
| 09/01/08 | Series E | 50M | Unknown |
People
Markus Cappel (Chief Business Officer)
Juan Jaen (SVP Drug Discovery)
Edward Mocarski (Board Member)
Roger Lucas (Board Member)
Margaret O’Connor (VP Operations)
Competitors
MacroGenics:
MacroGenics, Inc. is developing immunotherapeutics, including monoclonal antibodies, to treat patients with cancer, autoimmune disorders, allergy,… See Company Profile »
KaloBios Pharmaceuticals:
KaloBios has a rapidly growing pipeline of therapeutic antibody drugs directed against a wide variety of… See Company Profile »
News
Med device maker Acclarent's IPO flatlines — but could be revived
December 8, 2008 7:46 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Acclarent, maker of medical devices to treat ear, nose and… Continue reading ⟩
The genomic frontier: Personalized medicine in action
November 19, 2008 1:42 am
[Editor's note: As we've reported, the economic downturn and frozen IPO market have been especially tough on health care companies.… Continue reading ⟩
Cancer drug developer ChemoCentryx cancels IPO
November 17, 2008 8:31 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Mountain View, Calif.-based biotech firm ChemoCentryx announced that it withdrew… Continue reading ⟩